Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Relapsed Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma Intervention: Combination Product: CD19 CART Sponsors: Chinese PLA General Hospital; Shenzhen University; Shenzhen University General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials